Key result
Canola oil-enriched diets fail to improve FMD compared to a control oil blend.
Why the study?
Replacing saturated fatty acids with unsaturated fatty acids reduces cardiovascular risk, but the effect of replacing saturated fatty acids with monounsaturated fatty acids from conventional or high-oleic canola oils on flow-mediated dilation required evaluation.
Does partial replacement of saturated fatty acids with monounsaturated fatty acids from canola oil or high-oleic canola oil improve flow-mediated dilation in participants with or at risk of metabolic syndrome?
RCT (n=31)
double-blind
crossover
Yes
Does partial replacement of saturated fatty acids with monounsaturated fatty acids from canola oil or high-oleic canola oil improve flow-mediated dilation in participants with or at risk of metabolic syndrome?
Partial replacement of saturated fatty acids with monounsaturated fatty acids from conventional or high-oleic canola oil did not improve endothelial function measured by FMD in individuals with or at risk of metabolic syndrome.
Does not support canola MUFA enrichment for endothelial function; challenges expected vascular benefits in metabolic syndrome.
Partial replacement of saturated fatty acids (SFA) with unsaturated fatty acids is recommended to reduce cardiovascular disease (CVD) risk. Monounsaturated fatty acids (MUFA), including oleic acid, are associated with lower CVD risk. Measurement of flow-mediated dilation of the brachial artery (FMD) is the gold standard for measuring endothelial function and predicts CVD risk. This study examined the effect of partially replacing SFA with MUFA from conventional canola oil and high-oleic acid canola oil on FMD. Participants (n = 31) with an elevated waist circumference plus ≥1 additional metabolic syndrome criterion completed FMD measures as part of the Canola Oil Multi-Centre Intervention Trial 2 (COMIT-2), a multi-center, double-blind, three-period crossover, controlled feeding randomized trial. Diet periods were 6 weeks, separated by ≥4-week washouts. Experimental diets were provided during all feeding periods. Diets only differed by the fatty acid profile of the oils: canola oil (CO; 17.5% energy from MUFA, 9.2% polyunsaturated fatty acids (PUFA), 6.6% SFA), high-oleic acid canola oil (HOCO; 19.1% MUFA, 7.0% PUFA, 6.4% SFA), and a control oil blend (CON; 11% MUFA, 10% PUFA, 12% SFA). Multilevel models were used to examine the effect of the diets on FMD. No significant between-diet differences were observed for average brachial artery diameter (CO: 6.70 ± 0.15 mm, HOCO: 6.57 ± 0.15 mm, CON: 6.73 ± 0.14 mm; p = 0.72), peak brachial artery diameter (CO: 7.11 ± 0.15 mm, HOCO: 7.02 ± 0.15 mm, CON: 6.41 ± 0.48 mm; p = 0.80), or FMD (CO: 6.32 ± 0.51%, HOCO: 6.96 ± 0.49%, CON: 6.41 ± 0.48%; p = 0.81). Partial replacement of SFA with MUFA from CO and HOCO had no effect on FMD in participants with or at risk of metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2022) conducted an RCT in metabolic syndrome risk (n=31). Conventional canola oil (CO) and high-oleic acid canola oil (HOCO) vs. Control oil blend (11% MUFA, 10% PUFA, 12% SFA) was evaluated on flow-mediated dilation of the brachial artery (FMD) (p=0.81). Diets enriched with conventional (6.32%) or high-oleic canola oil (6.96%) had no significant effect on flow-mediated dilation compared to a control oil blend (6.41%; p=0.81).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: